1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
Holly LaFon
Holly LaFon
Articles (7135) 

Baron Funds Comments on Grifols SA

August 30, 2012 | About:

From Baron Funds' second quarter commentary:

Grifols SA (NASDAQ:GRFS) manufactures and sells plasma derivative healthcare products to hospitals and physicians globally. Grifols' NASDAQ-traded ADR increased over 24% during the quarter. Grifols' plasma proteins are an essential medical treatment for patients with primary immune deficiency, neurological diseases or hemophilia. Few companies can manufacture these treatments with a high degree of quality and consistency. Healthy demand for the product, coupled with a strong pricing environment, helped Grifols during the quarter.We continue to believe that Grifols will generate strong synergies from its 2011 acquisition of U.S.-based Talecris, and that Grifols will become significantly more profitable going forward. (Aaron Wasserman)


Rating: 3.3/5 (8 votes)

Comments

Please leave your comment:


GuruFocus has detected 3 Warning Signs with Grifols SA $GRFS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.

User Generated Screeners


pbarker46Dividend cos.
clemclem_99ultrasbetter
clemclem_99ultras
jebcolemanQuality&Value
CarstinSingapore Net-Nets
GKATUSAGKATUSA1
GKATUSAGKATUSA2
GKATUSAGKATUSA3
andrewgu999revenue growth
andrewgu999high operating margin
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK